Despite the ability of HRD cancers and PARPi per se to induce aberrantly damaged DNA accumulation to activate the cGAS-STING pathway, it is demonstrated that the combination of PARPi and STING agonist could trigger more robust STING activation, leading to reinforced downstream IFN signaling and T-cell and DC functions [173]. The gene discussed is STING1; the disease is cancer.